外部參考定價
參考文獻

1 2 3  Rémuzat, C; Urbinati, D; Mzoughi, O; El Hammi, E; Belgaied, W; Toumi, M. . Journal of Market Access & Health Policy (Systematic review). 2015, 3: 27675. PMC 4802694 . PMID 27123181. doi:10.3402/jmahp.v3.27675.
1 2 3 4 5 6 7 8 9  Toumi, Mondher; Rémuzat, Cécile; Vataire, Anne-Lise; Urbinati, Duccio.  (PDF). European Commission. 2014  [27 November 2019]. （原始内容存档 (PDF)于2020-07-26）.
1 2 3  Espin, J; Rovira, J; De Labry, AO.  (PDF). Health Action International. WHO/HAI. May 2011  [28 November 2019]. （原始内容存档 (PDF)于2020-11-28）. In all of the case study countries, a manufacturer submitting a new product for pricing is obliged to provide the price of the product in the reference countries. Failure to do so or to provide false information could lead to fines and penalties.
1 2  Rida, Nada Abdel; Ibrahim, Mohamed Izham Mohamed; Babar, Zaheer-Ud‐Din; Owusu, Yaw. . Journal of Pharmaceutical Health Services Research (Systematic review). 2017, 8 (4): 213–226. ISSN 1759-8893. S2CID 80486443. doi:10.1111/jphs.12191 （英语）.
↑  Bangalee, Varsha; Suleman, Fatima. . Global Journal of Health Science. 28 September 2018, 10 (10): 152. doi:10.5539/gjhs.v10n10p152.
1 2 3 4  Holtorf, Anke-Peggy; Gialama, Fotini; Wijaya, Kalman Emry; Kaló, Zoltán. . Value in Health Regional Issues (Review). 1 September 2019, 19: 122–131. ISSN 2212-1099. PMID 31416014. doi:10.1016/j.vhri.2019.04.003 .
↑  . www.haiweb.org. Health Action International. 2014  [28 November 2019]. （原始内容存档于2021-04-25）.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23  Saeed, Amna; Li, Zongjie; Kabba, John Alimamy; Yang, Caijun; Fang, Yu. . . Academic Press. 2019. ISBN 978-0-12-812736-0 （英语）.
1 2  Habl, C; Schneider, P; Sebesta, R; Németh, G. . European Journal of Public Health. November 2018, 28 (suppl_4). doi:10.1093/eurpub/cky212.217.
1 2 3 4  Raju, Priyanka Konduru Subramani. .  (Monograph). Academic Press. 2019: 209–228  [27 November 2019]. ISBN 978-0-12-813166-4. （原始内容存档于2022-02-11）.
1 2 3 4 5 6  . World Health Organization & Health Action International. May 2016: 123, 289  [2022-02-15]. （原始内容存档于2022-04-01）.  Mirror: 2008 original publication by WHO （页面存档备份，存于）.
1 2 3  Wirtz, VJ; Hogerzeil, HV; Gray, AL; Bigdeli, M; de Joncheere, CP; Ewen, MA; Gyansa-Lutterodt, M; Jing, S; Luiza, VL; Mbindyo, RM; Möller, H; Moucheraud, C; Pécoul, B; Rägo, L; Rashidian, A; Ross-Degnan, D; Stephens, PN; Teerawattananon, Y; 't Hoen, EF; Wagner, AK; Yadav, P; Reich, MR. . Lancet. 28 January 2017, 389 (10067): 403–476. PMC 7159295 . PMID 27832874. doi:10.1016/S0140-6736(16)31599-9.
1 2 3 4 5 6 7 8 9 10 11  Vogler, Sabine. . . Academic Press. 2019: 188–201. ISBN 978-0-12-812736-0 （英语）.
↑  Leopold, C; Vogler, S; Mantel-Teeuwisse, AK; de Joncheere, K; Leufkens, HG; Laing, R. . Health Policy (Amsterdam, Netherlands). January 2012, 104 (1): 50–60. PMID 22014843. doi:10.1016/j.healthpol.2011.09.008.
1 2 3  Vogler, Sabine; Schneider, Peter. . Medicine Price Surveys, Analyses and Comparisons (Academic Press). 1 January 2019: 247–268  [2022-02-15]. doi:10.1016/B978-0-12-813166-4.00014-0. （原始内容存档于2022-02-11）. If medicine prices are not regulated, they tend to vary between dispensaries and retailers of a country. To survey medicine prices in these contexts, the WHO/HAI methodology was developed, and it was frequently used for conducting price studies.
1 2 3  Schneider, Peter; Vogler, Sabine. . . Academic Press. 2019: 113–164  [2022-02-15]. ISBN 978-0-12-813166-4. （原始内容存档于2022-02-11）.
↑  . euripid.eu.   [2022-02-15]. （原始内容存档于2021-04-18）.
↑  Naina R. Verghese, Naina R.; Barrenetxea, Jon. . Journal of Market Access & Health Policy. 11 April 2019. doi:10.1080/20016689.2019.1601060.  使用|accessdate=需要含有|url= (帮助)
↑  Ding, Min; Eliashberg, Jehoshua; Stremersch, Stefan.  (Monograph). Springer Science & Business Media. 2013  [2022-02-15]. ISBN 978-1-4614-7801-0. （原始内容存档于2022-02-11） （英语）. Although they did not observe a direct effect of regulation on launch price, they did find an effect of regulation on launch timing. Apparently, regulatory restrictions are more useful to regulators in constraining the price of mature drugs rather than the price of newly launched drugs.
↑  Panteli, D; Arickx, F; Cleemput, I; Dedet, G; Eckhardt, H; Fogarty, E; Gerkens, S; Henschke, C; Hislop, J; Jommi, C; Kaitelidou, D; Kawalec, P; Keskimaki, I; Kroneman, M; Lopez Bastida, J; Pita Barros, P; Ramsberg, J; Schneider, P; Spillane, S; Vogler, S; Vuorenkoski, L; Wallach Kildemoes, H; Wouters, O; Busse, R. . Health Systems in Transition (Review). October 2016, 18 (5): 1–122. PMID 27929376.
↑  Hollis, Aidan; Grootendorst, Paul. . Medicine Price Surveys, Analyses and Comparisons (Academic Press). 1 January 2019: 31–43  [2022-02-15]. doi:10.1016/B978-0-12-813166-4.00004-8. （原始内容存档于2022-02-11）.
1 2  . Bloomberg. 1 February 2019  [8 December 2019]. （原始内容存档于2021-04-13） （英语）.
↑  Simmons-Duffin, Selena. . NPR.org. 19 September 2019  [8 December 2019]. （原始内容存档于2022-02-15） （英语）.
1 2  . datahelpdesk.worldbank.org. 2019  [30 November 2019]. （原始内容存档于2019-10-28）.
1 2 3  Acosta, A; Ciapponi, A; Aaserud, M; Vietto, V; Austvoll-Dahlgren, A; Kösters, JP; Vacca, C; Machado, M; Diaz Ayala, DH; Oxman, AD. . The Cochrane Database of Systematic Reviews (Systematic review). 16 October 2014, (10): CD005979. PMC 6703418 . PMID 25318966. doi:10.1002/14651858.CD005979.pub2.
↑  . www.haiweb.org. Health Action International.   [28 November 2019]. （原始内容存档于2021-04-25）.
↑   (PDF). haiweb.org. Health Action International. September 2014  [2022-02-15]. （原始内容存档 (PDF)于2022-03-03）.
↑  Dylst, Pieter. . Generics and Biosimilars Initiative Journal (Review). 15 August 2012, 1 (3–4): 127–131. doi:10.5639/gabij.2012.0103-4.028 .